TROP2 ADCs in Breast Cancer: Updates on the Latest Clinical Trial Data and AE Management
Webcast
1 CME ...OVERVIEW
TROP2 ADCs in Breast Cancer: Updates on the Latest Clinical Trial Data and AE Management is organized by Healio, Paradigm Medical Communications, LLC.
Release Date: June 6, 2025
Expiration Date: June 6, 2026
Description:
Join us for an enlightening and comprehensive program on the use of trophoblast cell surface antigen 2 (TROP2)-targeted antibody-drug conjugates (ADCs) in patients with breast cancer. Our faculty experts will offer valuable insights into available and emerging ADCs, present compelling patient case studies, and share their perspectives on optimizing therapeutic strategies, as well as address the management of potential adverse events (AEs) associated with TROP2-targeted ADCs. Don’t miss this opportunity to enhance your clinical practice and improve patient outcomes.
Learning Objectives:
Upon completion of this activity, participants should be able to:
- Analyze the latest clinical trial data for new and emerging TROP2-targeted ADCs for the treatment of mBC
- Apply clinical trial data and guideline recommendations when selecting patients with mBC to receive TROP2-targeted ADCs
- Review potential AEs associated with TROP2-targeted ADCs for patients with mBC
ACCREDITATION & CREDITS
Credits:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Paradigm Medical Communications, LLC and Educational Review Systems, Inc. Paradigm Medical Communications, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation Statement:
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation and Designation Statement:
acpe_logo_100pxEducational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 1.0 contact hour (0.10 CEU) submitted to CPE Monitor as early as 14 days after completion and no later than 60 days after completion. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time.
PA Continuing Education:
PAs may claim a maximum 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioner Continuing Education:
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
TARGET AUDIENCE
PhysicianPharmacistPhysician AssistantCliniciansOncologistsHematologistNurse PractitionersSPECIALITIES
HaematologyOncology
Quick Links